Among the attempts, Vanoye et al. (2022) successfully performed APC on 9480 cells from a 384 well plate (Nanion Technologies) to characterize the electrophysiology of different epilepsy-associated KCNQ2 variants and tested the effect of retigabine on all the cells, which is promising for APC to work as a HTS platform. This evidence concerns the gene KCNQ2 and epilepsy.